TY - JOUR
T1 - The effect of grape products on liver enzymes: A systematic review and meta‐analysis of randomized controlled trials
AU - Zamani, Mohammad
AU - Ashtary‐Larky, Damoon
AU - Hafizi, Nadia
AU - Naeini, Fatemeh
AU - Rezaei Kelishadi, Mahnaz
AU - Clark, Cain C. T.
AU - Davoodi, Sayed Hosein
AU - Asbaghi, Omid
N1 - Publisher Copyright:
© 2022 John Wiley & Sons Ltd.
PY - 2022/12
Y1 - 2022/12
N2 - The favorable influence of grape consumption on metabolic diseases has previously been shown in studies. We sought to assess the effects of grape intake on liver enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), in adults. We performed literature search in online databases, to find eligible randomized controlled trials (RCTs). we considered RCTs that met the following criteria: RCTs consisted of use of grape products on ALT, AST, and ALP in adults (≥18 years) with at least 2 weeks intervention duration. Pooling data from 11 trials showed that grape products intake significantly reduced ALP (p = .010), without any significant changes in ALT (p = .234) and AST (p = .300). In subgroup analysis, we found a significant reduction in ALP, ALT, and AST when the duration of intervention was ≥12 weeks, and when grape seed extract (GSE) was administered. The variable duration and dosage of intervention was one of the sources of bias in our meta-analysis. Additionally, participants involved in included studies had different physiological status and various age groups. Grape products administration may significantly improve ALT, AST, and ALP in adults in long-term interventions and/or when GSE is administered. It should be noted that the favorable effects of grape consumption were small and may not reach clinical importance.
AB - The favorable influence of grape consumption on metabolic diseases has previously been shown in studies. We sought to assess the effects of grape intake on liver enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), in adults. We performed literature search in online databases, to find eligible randomized controlled trials (RCTs). we considered RCTs that met the following criteria: RCTs consisted of use of grape products on ALT, AST, and ALP in adults (≥18 years) with at least 2 weeks intervention duration. Pooling data from 11 trials showed that grape products intake significantly reduced ALP (p = .010), without any significant changes in ALT (p = .234) and AST (p = .300). In subgroup analysis, we found a significant reduction in ALP, ALT, and AST when the duration of intervention was ≥12 weeks, and when grape seed extract (GSE) was administered. The variable duration and dosage of intervention was one of the sources of bias in our meta-analysis. Additionally, participants involved in included studies had different physiological status and various age groups. Grape products administration may significantly improve ALT, AST, and ALP in adults in long-term interventions and/or when GSE is administered. It should be noted that the favorable effects of grape consumption were small and may not reach clinical importance.
KW - grape
KW - liver
KW - meta-analysis
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85140239304&partnerID=8YFLogxK
U2 - 10.1002/ptr.7653
DO - 10.1002/ptr.7653
M3 - Review article
SN - 0951-418X
VL - 36
SP - 4491
EP - 4503
JO - Phytotherapy Research
JF - Phytotherapy Research
IS - 12
ER -